CD274 and non-small cell lung carcinoma: In the population of stage IV NSCLC patients without a driver mutation, immunotherapy with pembrolizumab is recommended either as a single agent in patients with high PDL1 expression, or in combination with chemotherapy in those with low PDL1 expression.